Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Myxoedema
ADR ID BADD_A02950
ADR Hierarchy
05      Endocrine disorders
05.02      Thyroid gland disorders
05.02.03      Thyroid hypofunction disorders
05.02.03.002      Myxoedema
23      Skin and subcutaneous tissue disorders
23.07      Skin and subcutaneous tissue disorders NEC
23.07.04      Skin and subcutaneous conditions NEC
23.07.04.007      Myxoedema
Description A condition characterized by a dry, waxy type of swelling (EDEMA) with abnormal deposits of MUCOPOLYSACCHARIDES in the SKIN and other tissues. It is caused by a deficiency of THYROID HORMONES. The skin becomes puffy around the eyes and on the cheeks. The face is dull and expressionless with thickened nose and lips. [MeSH]
MedDRA Code 10028665
MeSH ID D009230
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Myxedema | Myxoedema | Myxedemas
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00549Cyclophosphamide--
BADD_D00932Fluoxetine0.000091%
BADD_D01095Hydrogen iodide--
BADD_D01303Lithium carbonate--
BADD_D01304Lithium cation--
BADD_D01305Lithium hydroxide--
BADD_D01414Methimazole0.001083%
BADD_D01653Paclitaxel0.000799%
BADD_D01824Pravastatin0.000072%
BADD_D02100Sunitinib0.000799%
BADD_D02192Thalidomide--
The 1th Page    1    Total 1 Pages